Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) has acquired Halo Labs, a company specializing in imaging technologies for particle analysis in therapeutic products. The acquisition brings Halo's Aura™ platform, which offers full spectrum particle analysis capabilities complementary to Waters' existing Wyatt Technology™ Portfolio.
The Aura platform's key advantage lies in its ability to detect translucent process impurities in CAR T-cell therapies that are typically undetectable through standard methods. This technology will be integrated into Waters' large molecule development and QA/QC processes, enhancing their analytical capabilities for biopharmaceutical applications.
The acquisition is expected to have a negligible impact on Waters' income statement over the next 12 months.
Waters Corporation (NYSE:WAT) announced that CEO Udit Batra will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th, 2025, at 8:45AM Eastern Time. The event will be webcast live on Waters' Investor Relations website, with a replay available for 90 days.
Waters Corporation is a global leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences. With over 65 years of experience and 7,600+ employees across 100+ countries, the company collaborates with customers in laboratories, manufacturing sites, and hospitals to advance scientific innovation.
Waters (NYSE:WAT) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. The presentation will be accessible through a live webcast on the company's Investor Relations website, with replay availability until June 3rd, 2025.
Waters is a global leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences. The company employs 7,600 people across 100+ countries, working with customers in laboratories, manufacturing sites, and hospitals to advance scientific benefits.
Waters (NYSE:WAT) has expanded its Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection, enhancing capabilities for biopharmaceutical development and Quality Control laboratories. The system delivers significant improvements including:
- Up to 80x boost in sensitivity with MaxPeak™ Premier columns
- Over 3x improvement in day-to-day reproducibility
- Reduction in carryover by up to two orders of magnitude
- 40% reduction in common user errors
The platform is designed to simplify laboratory workflows and reduce out-of-specification results. All configurations are controlled by Waters Empower™ Chromatography Data System and support LIMS connectivity. The system has earned ACT Ecolabels from My Green Lab for sustainable manufacturing practices.
Waters (NYSE: WAT) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. CEO Udit Batra Ph.D. will engage in a fireside chat on Tuesday, March 11th, 2025 at 10:00AM Eastern Time.
The event will be accessible through a live webcast on Waters' Investor Relations website, with replay available for 90 days. Waters , with a 65-year legacy, operates globally as a leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences.
- Global presence in over 100 countries
- 7,600 employees worldwide
- Focus on medicine efficacy, food safety, water purity, and product quality
- Collaborates with laboratories, manufacturing sites, and hospitals
Waters (NYSE: WAT) reported strong Q4 2024 results with sales of $873 million, up 6% as reported and 8% in constant currency. Q4 highlights include 8% instrument growth and 9% recurring revenue growth in constant currency. Pharmaceutical sector showed robust performance, growing 10% in constant currency.
Full-year 2024 sales reached $2,958 million, flat year-over-year. The company achieved GAAP EPS of $10.71 and non-GAAP EPS of $11.86, up 1% from 2023 despite 5% foreign exchange headwinds. Waters generated strong cash flow with $762 million in operating cash flow and $744 million in free cash flow.
Looking ahead to 2025, Waters projects constant currency sales growth of 4.5% to 7.0%, with reported growth between 2.5% to 5.0% after accounting for currency impact. The company expects 2025 non-GAAP EPS between $12.70 and $13.00, facing approximately 4% headwind from foreign exchange.
Waters (NYSE:WAT) has launched the TA Instruments™ ElectroForce™ Apex 1 Mechanical Testing Instrument, designed for testing high-performance polymers and composites. The instrument offers 43% greater motor stroke range (100 mm) than competitors and can complete fatigue testing up to 30% faster, enhancing product development efficiency.
The system features automated controls and TuneIQ™ Technology for automatic instrument tuning without operator intervention. It includes improved break-stop capabilities and intelligent data acquisition to prevent computer overload. The instrument targets industries including medical device, polymer, aerospace, automotive, and additive manufacturing, where material strength and durability testing is crucial.